News

Study sheds light on platelet disorders


 

Platelets (blue) in a thrombus

Image by Andre E.X. Brown

Preclinical research has unearthed additional information about how platelets respond to shear stress, answering a 20-year-old question.

Investigators said this research provides new insights regarding platelet activation and clearance as well as insights into the pathophysiology of von Willebrand disease and related thrombocytopenic disorders.

The team described this work in Nature Communications.

Past research suggested that platelets respond to shear stress through a protein complex called GPIb-IX located on the platelet surface, but how this complex senses and responds to shear stress has remained a mystery for the past 20 years.

With the current study, investigators found that, contrary to popular belief, a certain region within GPIb-IX is structured.

This so-called mechanosensory domain (MSD) becomes unfolded on the platelet surface when von Willebrand factor binds to the GPIbα subunit of GPIb–IX under shear stress and imposes a pulling force on it.

The unfolding of MSD sets off a complex chain of events and sends an intracellular signal into the platelet that results in rapid platelet clearance.

“Every day, your bone marrow generates more than a billion platelets, and, every day, you clear the same number,” said study author Renhao Li, PhD, of Emory University School of Medicine in Atlanta, Georgia.

“It’s critical that your platelet count stays constant. Too few platelets can lead to . . . thrombocytopenia and may cause spontaneous bleeding or stroke. Thus, identifying the molecular ‘switch’ that triggers platelet clearance is important for designing new therapies to treat thrombocytopenia.”

The mechanism behind MSD-unfolding-induced platelet clearance is still unclear, but Dr Li said this research provides a good starting point for further inquiry into the phenomenon.

Recommended Reading

Smartphone app measures hemoglobin
MDedge Hematology and Oncology
FDA grants drug orphan designation for PNH
MDedge Hematology and Oncology
Gene therapy effective against SCD in mice
MDedge Hematology and Oncology
CBT may be best option for pts with MRD, doc says
MDedge Hematology and Oncology
Improvements needed in SCD care, report says
MDedge Hematology and Oncology
Study supports expanded prenatal genetic testing
MDedge Hematology and Oncology
Potential treatment strategy for dyskeratosis congenita
MDedge Hematology and Oncology
Drug granted orphan designation for MAS
MDedge Hematology and Oncology
Anemia linked to risk of death after stroke
MDedge Hematology and Oncology
Gene therapy accepted into PRIME program
MDedge Hematology and Oncology